Drug Profile
Research programme: reuptake inhibitors - Neurovance
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator DOV Pharmaceutical
- Developer Neurovance
- Class
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Cognition disorders; Major depressive disorder; Pain; Premenstrual dysphoric disorder; Substance-related disorders
- Discontinued Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cognition-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in USA